Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Paul TappendenChristopher CarrollJean HamiltonEva KaltenthalerRuth WongJonathan WadsleyLaura MossSabapathy P BalasubramanianPublished in: Health technology assessment (Winchester, England) (2020)
The National Institute for Health Research Health Technology Assessment programme.
Keyphrases
- locally advanced
- squamous cell carcinoma
- rectal cancer
- neoadjuvant chemotherapy
- radiation therapy
- phase ii study
- public health
- healthcare
- small cell lung cancer
- mental health
- quality improvement
- study protocol
- health information
- metastatic renal cell carcinoma
- human health
- risk assessment
- liver metastases
- climate change